Drug-Dietary Interactions: Over-the-Counter Medications, Herbs, and Dietary Supplements

  • Laurence J. KinsellaEmail author
  • George T. Grossberg
  • Neha Prakash


People crave autonomy in healthcare and will often reach for the pharmacy aisle before calling a doctor. Patients may be putting themselves at risk for toxicity and drug interactions with the expanding use of herbal medications, OTCs, and dietary supplements. Clinicians need to be aware of potential drug interactions between prescribed and nonprescribed substances. It is important to take a thorough medication history that includes dietary habits, OTCs, supplements, and herbal remedies to predict and prevent potential interactions.


Drug-dietary interactions Medication interactions Herb-drug interactions Dietary supplement interactions with drugs Over-the-counter medicine interactions 


  1. 1.
    Cvetanovich GL, Ramakrishnan P, Klein JP, Rao VR, Ropper AH. Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report. J Med Case Rep. 2011;5(1):34. Scholar
  2. 2.
    Center for Food Safety, Nutrition A. Dietary Supplements.
  3. 3.
    Brown AC. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series. Food Chem Toxicol. 2017;107(Pt A):449–71. Scholar
  4. 4.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78. Scholar
  5. 5.
    Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med. 2009;333(12):803–4. Scholar
  6. 6.
    Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116(7):478–85. Scholar
  7. 7.
    Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug–dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med. 2004;164(6):630–6. Scholar
  8. 8.
    Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol. 2016;18(2):262–76. Scholar
  9. 9.
    Sheikh HU, Mathew PG. Reversible cerebral vasoconstriction syndrome: updates and new perspectives. Curr Pain Headache Rep. 2014;18(5):414. Scholar
  10. 10.
    Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a poison control center system. J Med Toxicol. 2007;3(1):15–9. Scholar
  11. 11.
    Jang H-S, Roh SY, Jeong EH, Kim B-S, Sunwoo MK. Ginkgotoxin induced seizure caused by vitamin B6 deficiency. J Epilepsy Res. 2015;5(2):104–6. Scholar
  12. 12.
    Boyer EW, Shannon M. The Serotonin syndrome. N Engl J Med. 2009;352(11):1112–20. Scholar
  13. 13.
    Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35(10):1466. Scholar
  14. 14.
    Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8. Scholar
  15. 15.
    Carol ML. Hydroxycut weight loss dietary supplements: a contributing factor in the development of exertional rhabdomyolysis in three U.S. Army soldiers. Mil Med. 2013;178(9):e1039–42. Scholar
  16. 16.
    Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(04):430–2. Scholar
  17. 17.
    Mangi MA, Rehman H, Rafique M, Illovsky M. Energy drinks and the risk of cardiovascular disease: a review of current literature. Cureus. 2017;9(6):e1322. Scholar
  18. 18.
    Husain Z, Hussain K, Nair R. Diphenhydramine induced QT prolongation and torsade de pointes: an uncommon effect of a common drug. Cardiol J. 2010;17(5):509–11.PubMedGoogle Scholar
  19. 19.
    Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug? herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract. 2006;12(4):236–41. Scholar
  20. 20.
    Fakhar H, Hashemi TA. Effect of the garlic pill in comparison with Plavix on platelet aggregation and bleeding time. Iran J Ped Hematol Oncol. 2012;2(4):146–52.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Pedroso JL, Henriques Aquino CC, Escórcio Bezerra ML, et al. Ginkgo biloba and cerebral bleeding: a case report and critical review. Neurologist. 2011;17(2):89–90. Scholar
  22. 22.
    Finkelstein Y, Goel G, Hutson JR. Drug misuse in adolescents presenting to the emergency department. Pediatr Emerg Care. 2017;33(7):451–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. 2011;99(1):1–9. Scholar
  24. 24.
    Costa I, Mendonça MD, Silva VE, Calado S. Herbal supplements association with reversible cerebral vasoconstriction syndrome: a case report. J Stroke Cerebrovasc Dis. 2017 Mar;26(3):673–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Baharith H, Zarrin A. Khat ? A new precipitating factor for reversible cerebral vasoconstriction syndrome: a case report. J Med Case Rep. 2016;10(1):1159. Scholar
  26. 26.
    Tuladhar AM, Boogaarts HD, de Leeuw F-E, van Dijk E. Reversible cerebral vasoconstriction syndrome after chewing khat leaves. Cerebrovasc Dis. 2013;36(2):158–9. Scholar
  27. 27.
    Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM. The vitamin B6 paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicol in Vitro. 2017;44:206–12. Scholar
  28. 28.
    Bacharach R, Lowden M, Ahmed A. Pyridoxine toxicity small fiber neuropathy with dysautonomia. J Clin Neuromuscul Dis. 2017;19(1):43–6. Scholar
  29. 29.
    Chan H, Billmeier GJ, Evans WE. Lead poisoning from ingestion of Chinese herbal medicine. Clin Toxicol. 1977;10(3):273–81. Scholar
  30. 30.
    Gurley BJ, Steelman SC, Thomas SL. Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy. Clin Ther. 2015;37(2):275–301. Scholar
  31. 31.
    Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med. 2005 Apr;12(2):78–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee Y-P, Liao J-T, Cheng Y-W, et al. Inhibition of human alcohol and aldehyde dehydrogenases by acetaminophen: assessment of the effects on first-pass metabolism of ethanol. Alcohol. 2013;47(7):559–65. Scholar
  33. 33.
    Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. J Am Dent Assoc. 1999;130(3):397–407.CrossRefPubMedGoogle Scholar
  34. 34.
    Honig PK, Gillespie BK. Drug interactions between prescribed and over-the-counter medication 1. Drug Saf. 1995;13(5):296–303. Scholar
  35. 35.
    Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927–41. Scholar
  36. 36.
    Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–82. Scholar
  37. 37.
    Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68(3):231–7. Scholar
  38. 38.
    Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39(2):127–53. Scholar
  39. 39.
    Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs. 2009;69(13):1777–98. Scholar
  40. 40.
    Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–21. Scholar
  41. 41.
    Benotsch EG, Koester S, Martin AM, Cejka A, Luckman D, Jeffers AJ. Intentional misuse of over-the-counter medications, mental health, and polysubstance use in young adults. J Community Health. 2013;39(4):688–95. Scholar
  42. 42.
    Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st annual report. Clin Toxicol. 2015;52(10):1032–283. Scholar
  43. 43.
    Weight loss supplements. Amazon. Published July 5, 2017. Accessed 7 May 2017.
  44. 44.
    Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med. 2005;142(6):477–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Araujo JL, Worman HJ. Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Reports 2015.
  46. 46.
    Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy. 2001;21(5):647–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Narasimha A, Shetty PH, Nanjundaswamy MH, Viswanath B, Bada Math S. Hydroxycut? Dietary supplements for weight loss: can they induce mania? Aust N Z J Psychiatry. 2013;47(12):1205–6. Scholar
  48. 48.
    Dehoney S, Wellein M. Rhabdomyolysis associated with the nutritional supplement Hydroxycut. Am J Health Syst Pharm. 2009;66(2):142–8. Scholar
  49. 49.
    Hendrickson BP, Shaikh N, Occhiogrosso M, Penzner JB. Mania induced by <em>Garcinia cambogia</em>. Prim Care Companion CNS Disord. 2016.
  50. 50.
    Lopez AM, Kornegay J, Hendrickson RG. Serotonin toxicity associated with Garcinia cambogia over-the-counter supplement. J Med Toxicol. 2014;10(4):399–401. Scholar
  51. 51.
    Umemura T, Ichijo T, Matsumoto A. Severe hepatic injury caused by orlistat. Am J Med. 2006;119(8):e7.CrossRefPubMedGoogle Scholar
  52. 52.
    Harrison SA, Fecht W, Brunt EM, Neuschwander Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80–6. Scholar
  53. 53.
    Earnshaw I, Thachil J. Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evan’s syndrome. BMJ Case Rep. 2016:bcr2016217246.
  54. 54.
    de Moraes C, de Oliveira CA, Amaral MECD, Landini GA, Catisti R. Liver metabolic changes induced by conjugated linoleic acid in calorie-restricted rats. Arch Endocrinol Metab. 2017;61(1):45–53. Scholar
  55. 55.
    FDA warns consumers to stop using hydroxycut products risk of liver injury. http://www.fda.govdownloadsNewsEventsPublicHealthFocusUCM.pdf.
  56. 56.
    Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015;102:134–48. Scholar
  57. 57.
    Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12–23.PubMedGoogle Scholar
  58. 58.
    Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement-drug interactions. Am Fam Physician. 2017;96(2):101–7.PubMedGoogle Scholar
  59. 59.
    Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21(5):404–28. Scholar
  60. 60.
    Yuan C-S, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med. 2004;141(1):23–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415–26. Scholar
  62. 62.
    Yue QY, Jansson K. Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc. 2001;49(6):838.CrossRefPubMedGoogle Scholar
  63. 63.
    Shike M, Doane AS, Russo L, et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. J Natl Cancer Inst. 2014;106(9):dju189. Scholar
  64. 64.
    Izzo AA. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42(03):139–48. Scholar
  65. 65.
    Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharm Res. 2014;31(8):2035–43. Scholar
  66. 66.
    Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev. 2016;5(1):3135. Scholar
  67. 67.
    Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv. 1999;50(7):969–70. Scholar
  68. 68.
    Dalwood J, Dhillon R, Tibrewal P, Gupta N, Bastiampillai T. St John’s wort – is it safe in bipolar disorder? Aust N Z J Psychiatry. 2015;49(12):1226–7. Scholar
  69. 69.
    Stevinson C, Ernst E. Can St. John’s wort trigger psychoses? Int J Clin Pharmacol Ther. 2004;42(9):473–80.CrossRefPubMedGoogle Scholar
  70. 70.
    Tattelman E. Health effects of garlic. Am Fam Physician. 2005;72:103–6.PubMedGoogle Scholar
  71. 71.
    Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at heart trial. Integr Blood Press Control. 2016;9:9–21. Scholar
  72. 72.
    Shafiekhani M, Faridi P, Kojuri J, Namazi S. Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial. Avicenna J Phytomed. 2016;6(5):550–7.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? In: Cott JM, Eisenbrand G, editors. Mol Nutr Food Res 2008;52(7):764–71. Scholar
  74. 74.
    Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59(4):425–32. Scholar
  75. 75.
    Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician. 2003;68(8):1539–42.PubMedGoogle Scholar
  77. 77.
    Bruminhent J, Carrera P, Li Z, Amankona R, Roberts IM. Acute pancreatitis with saw palmetto use: a case report. J Med Case Rep. 2011;5(1):219. Scholar
  78. 78.
    Jipescu D, Patel A, Bohra H, Pientka A. Rare case of saw palmetto induced complete heart block. J Am Coll Cardiol. 2017;69(11):2310. Scholar
  79. 79.
    Villanueva S, González J. Coagulopathy induced by saw palmetto: a case report. Bol Asoc Med P R. 2009;101(3):48–50.PubMedGoogle Scholar
  80. 80.
    Federal register: mandatory guidelines for federal workplace drug testing programs. 2017.
  81. 81.
    Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76. Scholar
  82. 82.
    Clinical drug testing in primary care. Substance Abuse and Mental Health Services Adminstration. Published 2012. Accessed 25 Oct 2017.Google Scholar
  83. 83.
    Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010;67(16):1344–50. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Laurence J. Kinsella
    • 1
    • 2
    Email author
  • George T. Grossberg
    • 3
  • Neha Prakash
    • 4
  1. 1.Department of NeurologySSM Neuroscience InstituteSt. LouisUSA
  2. 2.Department of NeurologySt. Louis University School of MedicineSt. LouisUSA
  3. 3.Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral NeuroscienceSt. Louis University School of MedicineSt. LouisUSA
  4. 4.Department of NeurologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations